GEO vs GOVX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GEO and GOVX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GEO and GOVX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

The GEO Group is one of the largest private operators of secure detention and correctional facilities in the United States, and it also runs a growing electronic-monitoring and community-reentry business through its GEO Care and BI Incorporated units. The company owns and leases facilities that house federal, state, and local inmates and detainees, and it provides transportation, supervision, and monitoring services under government contracts. Historically structured as a real estate investment trust, GEO has at times shifted its tax treatment to prioritize debt reduction, so investors should check its current REIT status and capital-return posture rather than assume a fixed dividend policy.

Full GEO guide

GeoVax Labs, Inc. is a small, clinical-stage biotechnology company (listed on Nasdaq) that develops vaccines and immunotherapies using its Modified Vaccinia Ankara (MVA) viral-vector platform and a separate gene-directed cancer therapy. It is pre-revenue in the commercial sense: its value is tied to whether its experimental programs succeed in trials and eventually reach the market, not to product sales today.

Full GOVX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GEO drivers: ICE detention and transportation contracts; Facility reactivation and utilization.
• GOVX drivers: GEO-CM04S1 in immunocompromised patients; Gedeptin oncology program.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is policy and political exposure: a large share of revenue depends on federal immigration enforcement, so a change in administration, budget priorities, or court rulings could reduce detained populations and contract awards quickly. For GOVX, the risks here are severe and existential.

Pick GEO if you believe its drivers more; GOVX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GEO and GOVX guides.

GEO. These points are qualitative and tied to the asOf date; verify current figures, contract terms, and REIT status before acting. GEO is best understood as a policy-exposed operator whose earnings power hinges on government contract awards and utilization, so headline multiples matter less than the durability of its detention and monitoring contracts. Sentiment can move sharply on immigration-policy headlines in either direction.

GOVX. These figures are approximate, qualitative, and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech like GeoVax, traditional valuation multiples (P/E, price-to-sales) are not meaningful because there are no profits and little revenue. What matters instead is cash on hand, burn rate, dilution, and the odds attached to clinical and regulatory milestones, all of which can change quickly.

Headline figures (approximate, Jul 2026): GEO shows revenue trend Quarterly revenue has grown alongside expanded ICE contracts, with management raising its full-year outlook in 2026, earnings direction Q1 2026 earnings roughly doubled year over year on higher detention volumes and reactivated facilities, revenue mix Federal immigration (ICE) work has grown to roughly half of total revenue, a notable concentration, balance sheet Carries a meaningful debt load; management has prioritized deleveraging at times over distributions; GOVX shows revenue Minimal / pre-commercial; no meaningful product sales (any revenue is grant or collaboration related), profitability Deeply unprofitable; net loss roughly $21 million in 2025 as R&D and trial spending continue, cash runway Very tight; only a few million in cash and a going-concern opinion, funding operations into roughly mid-2026 before further raises, clinical stage Phase 2 for lead COVID vaccine GEO-CM04S1; Phase 1/2 completed for Gedeptin with a Phase 2 planned; GEO-MVA earlier.

GEO and GOVX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GEO and GOVX exposure against your real portfolio. It is not an investment adviser.